|
EXS73565 Clinical Trials
1 actively recruiting trial
No change since June 2026
Pipeline
Phase 1: 1
Top Sponsors
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1
Indications
- Waldenstrom's Macroglobulinemia (WM)1
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)1
- Relapsed or Refractory B-cell Malignancies1
- Marginal Zone Lymphoma (MZL)1
- Follicular Lymphoma ( FL)1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.